Compare · ILMN vs NVTA
ILMN vs NVTA
Side-by-side comparison of Illumina Inc. (ILMN) and Invitae Corporation (NVTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and NVTA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $31.30B.
- ILMN has hit the wire 14 times in the past 4 weeks while NVTA has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 18 for NVTA).
- Company
- Illumina Inc.
- Invitae Corporation
- Price
- -
- -
- Market cap
- $31.30B
- -
- 1M return
- -22.73%
- -
- 1Y return
- +72.44%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- 2015
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 18
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Latest ILMN
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
- Director Meister Keith A. sold $61,093,041 worth of shares (280,091 units at $218.12) (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $58,142 worth of shares (267 units at $217.76), decreasing direct ownership by 2% to 14,029 units (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
- Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Latest NVTA
- Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
- Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
- Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- Invitae Publishes its Environmental, Social and Governance (ESG) Report
- Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
- Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
- Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
- Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting